Abstract
Epstein-Barr virus (EBV) is associated with several lymphomas including Burkitt lymphoma; EBV-positive diffuse large B cell lymphoma, not otherwise specified; post-transplant lymphoproliferative disorders; extranodal NK/T cell lymphoma, nasal type; and chronic active EBV disease. EBV encodes several oncoproteins important in terms of B-cell immortalization; it also encodes proteins that potentiate lymphomagenesis. Host gene mutation/modification followed by EBV infection triggers lymphomas, though the host driver genes differ among lymphomas. Both congenital and acquired immunodeficiency greatly compromise cellular immunity and increase the rates of EBV-associated lymphoma. PD-1/PD-L1 pathway blockade is effective in treating EBV-associated lymphomas, as PDL-1 is overexpressed in these diseases, and is attributable to structural abnormalities in the 3' untranslated region and/or upregulation by viral genes.
| Original language | English |
|---|---|
| Title of host publication | Precision Cancer Therapies |
| Subtitle of host publication | Volume 2: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice |
| Publisher | wiley |
| Pages | 235-245 |
| Number of pages | 11 |
| ISBN (Electronic) | 9781119824572 |
| ISBN (Print) | 9781119824541 |
| DOIs | |
| Publication status | Published - 01-01-2024 |
All Science Journal Classification (ASJC) codes
- General Medicine